|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eli Lilly and Company |
| Information provided by: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT00035035 |
Purpose
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.
| Condition | Intervention | Phase |
|
Pancreatic Neoplasms Metastases, Neoplasm |
Drug: GEMZAR Drug: ALIMTA |
Phase III |
| MedlinePlus related topics: | Cancer Pancreatic Cancer |
| Drug Information available for: | Gemcitabine hydrochloride Gemcitabine Pemetrexed disodium Pemetrexed Pancrelipase Ultrase |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 115 Study Locations |
| Eli Lilly and Company |
More Information
| Study ID Numbers: | 5148, H3E-MC-JMES |
| First Received: | May 2, 2002 |
| Last Updated: | July 18, 2006 |
| ClinicalTrials.gov Identifier: | NCT00035035 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|